Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 14, 2024 10:54 ET | Source: Research and Markets

Chemotherapy Drugs Market Report 2024: Essential Growth Dynamics and Advancements to 2030

Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Chemotherapy Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.A...
April 26, 2024 04:15 ET | Source: Research and Markets

Global CDK 4/6 Inhibitor Drugs Market Outlook 2023-2035: A USD 66.63 Billion Market by 2035, Up From USD 9.03 Billion in 2022

Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "Global CDK 4/6 Inhibitor Drugs Market Outlook 2023-2035" report has been added to ResearchAndMarkets.com's offering.The global CDK 4/6 inhibitor...
September 05, 2023 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Shares Encore ELAINE-2 Poster Presentation at 2023 Metastatic Breast Cancer Research Conference

COLUMBUS, Ohio, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic...
May 25, 2023 17:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023

COLUMBUS, Ohio, May 25, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
April 13, 2023 10:18 ET | Source: Research and Markets

Chemotherapy Drugs Market Insights, Competitive Landscape, and Market Forecasts, 2027

Dublin, April 13, 2023 (GLOBE NEWSWIRE) -- The "Chemotherapy Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2027" drug pipelines has been added to ResearchAndMarkets.com's...
March 09, 2023 08:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid Biopsy

Prospective screening of subjects for ESR1 mutations will use the Guardant360 CDx blood test for companion diagnostic developmentPhase 3 study is supported by previously presented ELAINE-1 and...
May 31, 2022 15:25 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix to Present Updated Data from ELAINE-2 Clinical Trial of Lasofoxifene in Combination with Abemaciclib in Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation after Progression on Prior Therapies at the 2022 ASCO Annual Meeting

COLUMBUS, Ohio, May 31, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...